ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis

Rohit Bose, Wouter R. Karthaus, Joshua Armenia, Wassim Abida, Phillip J. Iaquinta, Zeda Zhang, John Wongvipat, Elizabeth V. Wasmuth, Neel Shah, Patrick S. Sullivan, Michael G. Doran, Ping Wang, Anna Patruno, Yilin Zhao, Deyou Zheng, Nikolaus Schultz, Charles L. Sawyers

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Half of all prostate cancers are caused by the TMPRSS2-ERG gene-fusion, which enables androgens to drive expression of the normally silent E26 transformation-specific (ETS) transcription factor ERG in prostate cells1-2. Recent genomic landscape studies of such cancers3-8 have reported recurrent point mutations and focal deletions of another ETS member, the ETS2 repressor factor ERF. Here we show these ERF mutations cause decreased protein stability and mostly occur in tumours without ERG upregulation. ERF loss recapitulates the morphological and phenotypic features of ERG gain in normal mouse prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF has tumour suppressor activity in the same genetic background of Pten loss that yields oncogenic activity by ERG. In the more common scenario of ERG upregulation, chromatin immunoprecipitation followed by sequencing indicates that ERG inhibits the ability of ERF to bind DNA at consensus ETS sites both in normal and in cancerous prostate cells. Consistent with a competition model, ERF overexpression blocks ERG-dependent tumour growth, and ERF loss rescues TMPRSS2-ERG-positive prostate cancer cells from ERG dependency. Collectively, these data provide evidence that the oncogenicity of ERG is mediated, in part, by competition with ERF and they raise the larger question of whether other gain-of-function oncogenic transcription factors might also inactivate endogenous tumour suppressors.

Original languageEnglish (US)
Pages (from-to)671-675
Number of pages5
JournalNature
Volume546
Issue number7660
DOIs
StatePublished - Jun 29 2017

Fingerprint

Prostate
Carcinogenesis
Mutation
Neoplasms
Prostatic Neoplasms
Transcription Factors
Up-Regulation
Protein Stability
Chromatin Immunoprecipitation
Gene Fusion
Androgen Receptors
Point Mutation
Androgens
DNA
Growth

ASJC Scopus subject areas

  • Medicine(all)
  • General

Cite this

Bose, R., Karthaus, W. R., Armenia, J., Abida, W., Iaquinta, P. J., Zhang, Z., ... Sawyers, C. L. (2017). ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature, 546(7660), 671-675. https://doi.org/10.1038/nature22820

ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. / Bose, Rohit; Karthaus, Wouter R.; Armenia, Joshua; Abida, Wassim; Iaquinta, Phillip J.; Zhang, Zeda; Wongvipat, John; Wasmuth, Elizabeth V.; Shah, Neel; Sullivan, Patrick S.; Doran, Michael G.; Wang, Ping; Patruno, Anna; Zhao, Yilin; Zheng, Deyou; Schultz, Nikolaus; Sawyers, Charles L.

In: Nature, Vol. 546, No. 7660, 29.06.2017, p. 671-675.

Research output: Contribution to journalArticle

Bose, R, Karthaus, WR, Armenia, J, Abida, W, Iaquinta, PJ, Zhang, Z, Wongvipat, J, Wasmuth, EV, Shah, N, Sullivan, PS, Doran, MG, Wang, P, Patruno, A, Zhao, Y, Zheng, D, Schultz, N & Sawyers, CL 2017, 'ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis', Nature, vol. 546, no. 7660, pp. 671-675. https://doi.org/10.1038/nature22820
Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017 Jun 29;546(7660):671-675. https://doi.org/10.1038/nature22820
Bose, Rohit ; Karthaus, Wouter R. ; Armenia, Joshua ; Abida, Wassim ; Iaquinta, Phillip J. ; Zhang, Zeda ; Wongvipat, John ; Wasmuth, Elizabeth V. ; Shah, Neel ; Sullivan, Patrick S. ; Doran, Michael G. ; Wang, Ping ; Patruno, Anna ; Zhao, Yilin ; Zheng, Deyou ; Schultz, Nikolaus ; Sawyers, Charles L. / ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. In: Nature. 2017 ; Vol. 546, No. 7660. pp. 671-675.
@article{4208da52f43142ab93cecd86a2a24f6b,
title = "ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis",
abstract = "Half of all prostate cancers are caused by the TMPRSS2-ERG gene-fusion, which enables androgens to drive expression of the normally silent E26 transformation-specific (ETS) transcription factor ERG in prostate cells1-2. Recent genomic landscape studies of such cancers3-8 have reported recurrent point mutations and focal deletions of another ETS member, the ETS2 repressor factor ERF. Here we show these ERF mutations cause decreased protein stability and mostly occur in tumours without ERG upregulation. ERF loss recapitulates the morphological and phenotypic features of ERG gain in normal mouse prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF has tumour suppressor activity in the same genetic background of Pten loss that yields oncogenic activity by ERG. In the more common scenario of ERG upregulation, chromatin immunoprecipitation followed by sequencing indicates that ERG inhibits the ability of ERF to bind DNA at consensus ETS sites both in normal and in cancerous prostate cells. Consistent with a competition model, ERF overexpression blocks ERG-dependent tumour growth, and ERF loss rescues TMPRSS2-ERG-positive prostate cancer cells from ERG dependency. Collectively, these data provide evidence that the oncogenicity of ERG is mediated, in part, by competition with ERF and they raise the larger question of whether other gain-of-function oncogenic transcription factors might also inactivate endogenous tumour suppressors.",
author = "Rohit Bose and Karthaus, {Wouter R.} and Joshua Armenia and Wassim Abida and Iaquinta, {Phillip J.} and Zeda Zhang and John Wongvipat and Wasmuth, {Elizabeth V.} and Neel Shah and Sullivan, {Patrick S.} and Doran, {Michael G.} and Ping Wang and Anna Patruno and Yilin Zhao and Deyou Zheng and Nikolaus Schultz and Sawyers, {Charles L.}",
year = "2017",
month = "6",
day = "29",
doi = "10.1038/nature22820",
language = "English (US)",
volume = "546",
pages = "671--675",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7660",

}

TY - JOUR

T1 - ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis

AU - Bose, Rohit

AU - Karthaus, Wouter R.

AU - Armenia, Joshua

AU - Abida, Wassim

AU - Iaquinta, Phillip J.

AU - Zhang, Zeda

AU - Wongvipat, John

AU - Wasmuth, Elizabeth V.

AU - Shah, Neel

AU - Sullivan, Patrick S.

AU - Doran, Michael G.

AU - Wang, Ping

AU - Patruno, Anna

AU - Zhao, Yilin

AU - Zheng, Deyou

AU - Schultz, Nikolaus

AU - Sawyers, Charles L.

PY - 2017/6/29

Y1 - 2017/6/29

N2 - Half of all prostate cancers are caused by the TMPRSS2-ERG gene-fusion, which enables androgens to drive expression of the normally silent E26 transformation-specific (ETS) transcription factor ERG in prostate cells1-2. Recent genomic landscape studies of such cancers3-8 have reported recurrent point mutations and focal deletions of another ETS member, the ETS2 repressor factor ERF. Here we show these ERF mutations cause decreased protein stability and mostly occur in tumours without ERG upregulation. ERF loss recapitulates the morphological and phenotypic features of ERG gain in normal mouse prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF has tumour suppressor activity in the same genetic background of Pten loss that yields oncogenic activity by ERG. In the more common scenario of ERG upregulation, chromatin immunoprecipitation followed by sequencing indicates that ERG inhibits the ability of ERF to bind DNA at consensus ETS sites both in normal and in cancerous prostate cells. Consistent with a competition model, ERF overexpression blocks ERG-dependent tumour growth, and ERF loss rescues TMPRSS2-ERG-positive prostate cancer cells from ERG dependency. Collectively, these data provide evidence that the oncogenicity of ERG is mediated, in part, by competition with ERF and they raise the larger question of whether other gain-of-function oncogenic transcription factors might also inactivate endogenous tumour suppressors.

AB - Half of all prostate cancers are caused by the TMPRSS2-ERG gene-fusion, which enables androgens to drive expression of the normally silent E26 transformation-specific (ETS) transcription factor ERG in prostate cells1-2. Recent genomic landscape studies of such cancers3-8 have reported recurrent point mutations and focal deletions of another ETS member, the ETS2 repressor factor ERF. Here we show these ERF mutations cause decreased protein stability and mostly occur in tumours without ERG upregulation. ERF loss recapitulates the morphological and phenotypic features of ERG gain in normal mouse prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF has tumour suppressor activity in the same genetic background of Pten loss that yields oncogenic activity by ERG. In the more common scenario of ERG upregulation, chromatin immunoprecipitation followed by sequencing indicates that ERG inhibits the ability of ERF to bind DNA at consensus ETS sites both in normal and in cancerous prostate cells. Consistent with a competition model, ERF overexpression blocks ERG-dependent tumour growth, and ERF loss rescues TMPRSS2-ERG-positive prostate cancer cells from ERG dependency. Collectively, these data provide evidence that the oncogenicity of ERG is mediated, in part, by competition with ERF and they raise the larger question of whether other gain-of-function oncogenic transcription factors might also inactivate endogenous tumour suppressors.

UR - http://www.scopus.com/inward/record.url?scp=85021672279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021672279&partnerID=8YFLogxK

U2 - 10.1038/nature22820

DO - 10.1038/nature22820

M3 - Article

C2 - 28614298

AN - SCOPUS:85021672279

VL - 546

SP - 671

EP - 675

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7660

ER -